GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Research & Development

BCAL Diagnostics (ASX:BDX) Research & Development : A$2.94 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is BCAL Diagnostics Research & Development?

Research & Development is the aggregate amount of research and development expenses during the year. BCAL Diagnostics's Research & Development for the six months ended in Dec. 2023 was A$2.05 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 was A$2.94 Mil.

BCAL Diagnostics Research & Development Historical Data

The historical data trend for BCAL Diagnostics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BCAL Diagnostics Research & Development Chart

BCAL Diagnostics Annual Data
Trend Jun22 Jun23
Research & Development
1.12 3.24

BCAL Diagnostics Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
Research & Development Get a 7-Day Free Trial 0.96 0.16 2.35 0.89 2.05

BCAL Diagnostics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$2.94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BCAL Diagnostics  (ASX:BDX) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

BCAL Diagnostics Research & Development Related Terms

Thank you for viewing the detailed overview of BCAL Diagnostics's Research & Development provided by GuruFocus.com. Please click on the following links to see related term pages.

BCAL Diagnostics (ASX:BDX) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » BCAL Diagnostics Ltd (ASX:BDX) » Definitions » Research & Development
Comparable Companies
ASX:GTG ASX:CTE ASX:LDX ASX:IBX ASX:RHY ASX:IIQ ASX:GSS ASX:MAP TMO DHR SHSE:603259 IQV IDXX A XSWX:LONN MTD ICLR LH ILMN DGX
Traded in Other Exchanges
N/A
Address
Queen Victoria Building, GPO Box Q128, Sydney, NSW, AUS, 1230
Website
https://www.bcaldiagnostics.com
BCAL Diagnostics Ltd is a biotechnology company developing a novel blood screening test to improve the early diagnosis and monitoring of breast cancer by identifying, measuring, and validating specific biomarkers enriched from patient's blood. The BCAL technology utilizes a single blood test on multiple levels including disease detection, diagnostic mass screening, and post-intervention.